Dulaglutide
FDA ApprovedAlso known as: Trulicity
GLP-1 AgonistLast reviewed: April 28, 2026
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by Eli Lilly as a predecessor to tirzepatide. One of the most prescribed GLP-1 agonists globally.
Mechanism of Action
A GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Common Uses
- Type 2 diabetes
- Cardiovascular risk reduction
- Moderate weight loss
- Blood sugar regulation
Known Risks
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis (rare)
- Thyroid C-cell tumors (animal studies)
- Injection site reactions
- Hypoglycemia when combined with insulin
Regulatory Status
FDA-approved as Trulicity (2014) for type 2 diabetes and cardiovascular risk reduction (REWIND trial). Once-weekly injection via single-dose pen. One of the top-selling GLP-1 drugs globally.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
0.75 mg → 4.5 mg (titrated)
Frequency
Once weekly
Cycle Length
Ongoing
Pre-filled single-dose pen. Inject in abdomen, thigh, or upper arm. No reconstitution needed. Titrate from 0.75 mg every 4 weeks as tolerated.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.